- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cushing syndrome
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 618KB)
Osilodrostat – March 2024
Osilodrostat: Tablet 1 mg, Tablet 5 mg; Isturisa®
Last updated
30 May 2025